Cliff Asness's TNXP Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 882,595 shares of Tonix Pharmaceuticals Holding Corp. (TNXP) worth $11.26 M, representing 0.00% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Cliff Asness has maintained this position in TNXP for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 721,387 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Tonix Pharmaceuticals Holding (TNXP) Holding Value Over Time
Track share changes against reported price movement
Quarterly Tonix Pharmaceuticals Holding (TNXP) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +721,387 | Add 447.49% | 882,595 | $12.76 |
| Q1 2026 | +141,188 | Add 705.23% | 161,208 | $13.75 |
| Q4 2025 | +20,020 | New Buy | 20,020 | $15.62 |
Cliff Asness's Tonix Pharmaceuticals Holding Investment FAQs
Cliff Asness first purchased Tonix Pharmaceuticals Holding Corp. (TNXP) in Q4 2025, acquiring 20,020 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Tonix Pharmaceuticals Holding Corp. (TNXP) for 3 quarters since Q4 2025.
Cliff Asness's largest addition to Tonix Pharmaceuticals Holding Corp. (TNXP) was in Q2 2026, adding 882,595 shares worth $11.26 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 882,595 shares of Tonix Pharmaceuticals Holding Corp. (TNXP), valued at approximately $11.26 M.
As of the Q2 2026 filing, Tonix Pharmaceuticals Holding Corp. (TNXP) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Tonix Pharmaceuticals Holding Corp. (TNXP) was 882,595 shares, as reported at the end of Q2 2026.